Related Experiment Video
Updated: Jun 30, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
Platelet dysfunction in migraine: effect of self-medication with aspirin
Thrombosis and Haemostasis
|November 30, 1976
Summary
Migraine patients show increased platelet aggregation, indicated by a lower circulating microembolic index (CMI). Aspirin use in migraineurs improved CMI, suggesting platelet inhibitors may help manage this condition.
Area of Science:
- Neurology
- Hematology
- Cardiovascular Research
Background:
- Platelet aggregation is implicated in various vascular conditions.
- Migraine pathophysiology may involve microembolic events and platelet activation.
Purpose of the Study:
- To investigate platelet aggregation in migraine patients using the circulating microembolic index (CMI).
- To compare CMI in untreated migraineurs, migraineurs self-medicating with aspirin, and healthy controls.
Main Methods:
- Blood samples were collected to determine CMI by comparing counts in EDTA-formalin and DTA alone.
- Platelet aggregates were quantified, with ratios indicating the extent of aggregation.
- Study included 26 untreated migraineurs, 19 migraineurs on aspirin, and 20 healthy controls.
Main Results:
- Untreated migraineurs exhibited a significantly lower mean CMI (0.77) compared to normal controls (0.94).
- Migraineurs who self-medicated with aspirin showed a mean CMI of 0.88, significantly higher than untreated patients.
- Aspirin-treated migraineurs' CMI was not significantly different from normal controls.
Conclusions:
- Migraineurs demonstrate excessive platelet aggregation, contributing to a lower circulating microembolic index.
- Self-administration of aspirin appears to correct the abnormal CMI in migraineurs.
- Findings suggest that platelet aggregation is a factor in migraine and may be modulated by antiplatelet agents like aspirin.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...